Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 8, 2014
Reporting Period: Events occurring between November 26, 2014, and December 12, 2014.
Key Financial Metrics and Capital Activities
This filing reports unregistered sales of equity securities and warrant exercises rather than standard operating financial metrics. Key capital activity figures include:
- Cash Raised from Equity Sale: $250,000 for 966,667 shares of common stock.
- Services Compensation: $38,000 value for 162,500 shares of common stock issued for services.
- Cash Raised from Warrant Exercise: $33,000 for 110,000 shares of common stock.
- Total Cash Inflow Reported: $283,000.
- Warrants Issued: 441,667 warrants issued with equity sale; 110,000 additional warrants issued with warrant exercise.
Note: The filing text does not provide clear values for revenue, net profit, operating cash flow, margins, total debt, or liquidity positions.
Material Changes and Transactions
The filing details three distinct capital events:
- Private Placement (Nov 28 - Dec 11, 2014): Issuance of 966,667 shares for $250,000. Subscribers received warrants for 441,667 shares with tiered exercise prices ($0.40, $0.50, and $0.75) and a five-year term.
- Stock for Services (Nov 26 - Nov 30, 2014): Issuance of 162,500 shares valued at $38,000 in consideration for services rendered.
- Warrant Repricing and Exercise (Dec 12, 2014): Issuance of 110,000 shares via warrant exercise at a reduced price of $0.30 per share (total $33,000). This was part of a limited-time repricing program. Purchasers received additional warrants for 110,000 shares at $0.75 per share, exercisable until December 12, 2016.
Guidance, Risks, and Contingencies
Regulatory Basis: All transactions relied upon Section 4(a)(2) of the Securities Act of 1933 as transactions not involving a public offering. The Company did not use general solicitation or advertising.
Investor Status: The Company reasonably believes all investors are accredited investors who had access to the Company's 10-K, 10-Q, and 8-K filings.
Warrant Terms: Additional warrants issued on December 12, 2014, are redeemable by the Company under certain circumstances.
Note: The filing text does not provide clear values for future guidance, management outlook, or specific risk factors beyond the standard disclosure of unregistered sales.
Investor Verification Checklist
- Verify the dilution impact of the 1,239,167 total shares issued (966,667 + 162,500 + 110,000) on existing shareholders.
- Confirm the total number of outstanding warrants following the issuance of 551,667 new warrants (441,667 + 110,000).
- Review the specific "certain circumstances" under which the December 2014 warrants are redeemable by the Company.
- Assess the financial impact of the $38,000 non-cash compensation expense on the upcoming quarterly or annual report.
- Validate the Company's cash position post-transaction to ensure sufficient liquidity for operations.